Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monographs Not Viable for Unapproved Prescription Drug Review, FDA Says

Executive Summary

A monograph system is not a viable approach for evaluating the safety and efficacy of prescription drugs that are marketed without FDA approval, agency officials told an overflow crowd during a Jan. 9 workshop on unapproved drugs

You may also be interested in...



Counterfeit Drugs, Food Safety Are Expected Focus Of New FDA Bill In House

Tightened security for counterfeit drugs and food imports are slated to be addressed in another bill aimed at boosting FDA's oversight powers, Energy and Commerce Committee Chairman John Dingell, D-Mich., said during markup of drug safety legislation

Counterfeit Drugs, Food Safety Are Expected Focus Of New FDA Bill In House

Tightened security for counterfeit drugs and food imports are slated to be addressed in another bill aimed at boosting FDA's oversight powers, Energy and Commerce Committee Chairman John Dingell, D-Mich., said during markup of drug safety legislation

FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions

FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval

UsernamePublicRestriction

Register

PS047951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel